Compare Abbott Laboratories (ABT) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Allbirds Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Allbirds Inc trades at $3.43 (market cap $30.69M). The key difference: Abbott Laboratories is far larger — about 5439.6× Allbirds Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| ABT | BIRD | |
|---|---|---|
Market Cap | $166.94B | $30.69M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $16.99 |
52-Week Low | $82.57 | $2.39 |
Enterprise Value | $193.69B | $49.56M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BIRD (Smartbird) trades at $3.47, down 9.87% today, amid a complete pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with negative cash flows and widening losses, though revenue decline has slowed. Recent news highlights the strategic rebranding and new CEO appointment, driving volatile price action. Analyst consensus remains cautious with 78.57% hold ratings, reflecting uncertainty around the business transformation.
Outlook is highly speculative given the radical business model shift. The AI pivot offers growth potential but carries execution risks amid persistent losses and negative equity. Investors face significant volatility as the company transitions, with success dependent on securing AI infrastructure contracts and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
